4.5B
People with no easy access to blood testing
₹2,000
Average full panel cost at Indian pathology lab
8 min
Time to full results with this device
$10B
India diagnostics market annually
The pathology lab
is broken.
You feel unwell. You go to a doctor. The doctor sends you to a pathology lab. You register, wait, give blood, go home, wait again — sometimes 24 hours, sometimes more. You collect a printout of numbers with no context. You go back to the doctor to understand what the numbers mean. The doctor has 7 minutes.
In a tier-2 Indian city, this process takes two days and costs ₹2,000. In a village, the nearest lab may be 40 kilometres away. In most of Africa, it may not exist at all. The pathology lab model was designed for a world without smartphones, microfluidics, or AI. That world no longer exists.
"The pathology lab is right in your home. You test when you want. You know what your body is telling you. No intermediary. No waiting. No wrong results."
How it works —
simpler than you think.
1
Prick your finger — one drop
Exactly like a glucometer. A lancet device produces one small drop of blood — 10 to 50 microlitres. No vein. No nurse. No sitting in a waiting room.
2
Place the drop on the test cartridge
A single-use microfluidic cartridge — pre-loaded with reagents for every parameter. The blood flows through microscopic channels, each designed to react with specific biomarkers. The cartridge costs ₹200–400. It is the razor blade in the razor blade model.
3
Insert into the device — plug into your phone
The device reads the optical, electrochemical, and fluorescent signals from the cartridge simultaneously. Connected via USB-C or Lightning to your phone. The reader itself is reusable, lasts years, costs ₹3,000–5,000 once.
4
Results and AI analysis in 8 minutes
The app receives raw signal data, processes it against calibrated reference ranges, and delivers your complete blood panel with plain-language AI analysis — not just numbers but what they mean together, in context, for your age, gender, and health history.
What it measures —
the complete panel.
CBC
Haemoglobin, WBC, RBC, platelets, haematocrit
Glucose & HbA1c
Current blood sugar and 3-month average
Lipid Panel
Total cholesterol, HDL, LDL, triglycerides
Liver Function
ALT, AST, ALP, bilirubin
Kidney Function
Creatinine, urea, uric acid, eGFR
Thyroid
TSH — the single most important thyroid marker
Inflammation
CRP — cardiac and systemic inflammation marker
Iron Studies
Serum ferritin, iron, TIBC
Vitamins
Vitamin D, Vitamin B12
What the AI does —
what no printout ever did.
A lab report gives you numbers. The AI gives you understanding. Not just "your haemoglobin is 11.2 and normal is 13.5" — but what that number means in the context of your other results, your age, your gender, your history, and what you should do about it.
Sample AI Analysis · 44-year-old woman
HAEMOGLOBIN
11.2 g/dL ↓ (Normal: 12.0–15.5)
Below normal. Combined with your ferritin of 8 ng/mL and serum iron of 42 mcg/dL — this pattern is consistent with iron deficiency anaemia. This is the most common nutritional deficiency globally and is very treatable. Recommend increasing iron-rich foods and consider supplementation. Confirm with your doctor — a short course of iron tablets typically resolves this in 8–12 weeks.
HbA1c
5.9% ⚠️ (Normal: below 5.7%)
Pre-diabetic range. This is an early warning — not diabetes, but a signal that blood sugar regulation is under stress. At this level, lifestyle intervention — reduced refined carbohydrates, 30 minutes of daily walking — has a very high success rate in reversing the trend. Retest in 3 months. See your doctor to discuss.
VITAMIN D
18 ng/mL ↓ (Optimal: 40–60)
Deficient. Very common in India, particularly in urban populations with limited sun exposure. Low Vitamin D is associated with fatigue, bone density loss, and immune function. A daily supplement of 2000 IU is safe and effective. Retest in 3 months.
The Theranos lesson —
why this time is different.
The Theranos Warning: Elizabeth Holmes had exactly this vision in 2013. She failed — not because the concept was wrong, but because the technology was not ready and she chose to fake results rather than wait. She destroyed trust in the entire category and went to prison. The concept was vindicated. The execution was fraudulent.
What changed since 2013: Microfluidics miniaturisation has advanced by an order of magnitude. Electrochemical biosensors now achieve clinical-grade accuracy at micro volumes. Lab-on-chip technology has been validated in peer-reviewed studies at Johns Hopkins, MIT, and IIT Bombay. The FDA has approved point-of-care multiplex panels. The science that Theranos pretended to have — now genuinely exists.
The business model —
razor and razor blade.
The Device (Razor)
₹3,000–5,000
One-time purchase. Reusable for years. USB-C connection. Works with any Android or iPhone. Sold through pharmacies, Amazon, direct.
Test Cartridge (Blade)
₹250–400 per test
Single-use. Pre-loaded with reagents. Shelf life 18 months. Subscription option: ₹199/month for 2 tests. This is the recurring revenue engine.
AI Analysis App
₹99/month
Health history tracking. Trend analysis. Doctor-sharing feature. Family accounts. Medication interaction alerts. Freemium base, premium AI features.
B2B — Corporates & Clinics
₹500–800 per test
Employee health programmes. Rural clinics. Insurance companies offering preventive health incentives. Government ASHA worker toolkit.
The 5-year
development roadmap.
Year 1
Prototype and validation. Build a working prototype using existing lab-on-chip components. Validate accuracy against reference lab for 5 parameters — glucose, CBC, CRP, creatinine, TSH. Target accuracy: within 10% of clinical lab reference.
Year 2
Expand panel and file regulatory. Expand to full 9-parameter panel. Begin CDSCO regulatory filing in India — the most accessible major market for medical device approval. Build AI analysis engine on clinical validation dataset.
Year 3
Pilot launch. 10,000 devices in 3 Indian cities. Partner with 2 insurance companies. Corporate wellness pilot with 5 large employers. Refine cartridge manufacturing for cost reduction.
Year 4
National rollout India + Southeast Asia. Pharmacy chains, e-commerce, direct-to-consumer. ASHA worker toolkit launch for rural health. Series B funding for international expansion.
Year 5
Global. FDA 510(k) filing for US market. Africa expansion — the single largest unserved diagnostics market on earth. 1 million active users. The pathology lab is in your home.
Who should
build this.
A biomedical engineer with microfluidics experience. A software engineer who understands biosignal processing. A clinician — doctor or pathologist — who understands what the numbers mean clinically. And a business person who can navigate regulatory pathways in India.
India is the right place to build this first. CDSCO is more accessible than FDA. The market is enormous. The pain is acute. IIT Bombay, IISc Bangalore, and AIIMS all have the relevant research capability. The diagnostics industry in India is fragmented and ready for disruption. The first company to crack accuracy at this price point owns the market.
And next year — the founder of this idea intends to start testing. 😊
Open Source · No Patent · No Equity Required
The pathology lab belongs in every home.
This idea is released freely. No patent. No equity stake required. Build it, commercialise it, improve it. The only condition — make it affordable. The people who need this most are the ones who can least afford the current pathology system. Price it for them.
— Pawan Bhatia · NextGen Economics · Bangalore, India · June 2026